Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
https://doi.org/10.37489/2588-0519-2020-S4-4-7
Abstract
There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium aminodihydrophthalazindione at COVID-19 have not been found. The use of sodium aminodihydrophthalazindione in the treatment of COVID-19 is possible only in clinical trials.
About the Authors
V. M. Tsvetov
Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659
Chelyabinsk
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet
Oslo
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9a4584fc97b7-4b9c-8b45-c94f423d942a&t=
2. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017 Jul;39(5):517-528. DOI: 10.1007/s00281-017-0639-8
3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):10331034. DOI: 10.1016/S0140-6736(20)30628-0
4. Turmova EP, Grigoryuk AA, Bichkov EA, Markelova EV, Chihkalovets IV. Studying of application immunomodulator «Galavit» at experimental atherosclerosis. Bulletin of the East Siberian Scientific Center SBRAMS. 2012;85(3):232-326. (In Russ).
5. Artyushkova EB, Blinkov YuYu, Frolova OG et al. Experimental basis for the combined use of Mexicor® and Galavit® in the diffused peritonitis. Modern problems of science and education. 2017;(6). (In Russ). URL: http://www.science-education.ru/ru/article/view?id=27334 (дата обращения: 28.04.2020).
6. Yarmolinskaya MI et al. Patogeneticheskoe obosnovanie primeneniya immunomodulyatora» Galavit» v terapii naruzhnogo genital’nogo endometrioza. ZHurnal Rossijskogo obshchestva akusherov-ginekologov. 2008;(4):29-30. (In Russ).
7. Tsaregorodtseva MV. Prognosticheski znachimye infekcionnye faktory v formirovanii autoimmunnogo ooforita pri hronicheskih vospalitel’nyh zabolevaniyah organov malogo taza. Vestnik poslediplomnogo medicinskogo obrazovaniya. 2011;(4):1-7. (In Russ).
8. Serov VN, Tsaregorodtseva MV, Koroleva AV. Role of the immunomodulatory effect of Galavit in the treatment of patients with chronic small pelvic inflammatory diseases of chlamydial genesis. Russian Bulletin of Obstetrician-Gynecologist. 2011;11(3):17-20. (In Russ).
9. Prilepskaya VN, Bebneva TN. Effektivnost’ immunomodulyatora Galavita v lechenii vospalitel’nyh zabolevanij organov malogo taza. RMJ. 2013;21(1):31-38. (In Russ).
10. Kazeko NI et al. Immunomodulatory therapy of secondary chronic pyelonephritis on urolithiasis. Medicinskaya nauka i obrazovanie Urala. 2017;18(2):33-38. (In Russ).
11. Trinitatsky YuV. Klinikoimmunologicheskaya effektivnost’ immunomodulyatora «Galavit» pri lechenii rasseyannogo skleroza. Lechaschi Vrac. 2003;(6):27-30. (In Russ).
12. Pokrovskiy AV, Mkhitarova LA, Tsarevт VN. Predictive value of pro-inflammatory cytokines when determining indications for applicating Galavit inhalation in complex treatment of COPD. Bulletin of the Dagestan State Medical Academy. 2014;10(1):19-23. (In Russ).
13. Sologub TV, Osinovets OY. Using immunomodulating drug galavit in treatment of influenza. Klinicist. 2012;(2). (In Russ).
14. Sologub TV, Osinovets OY. Immunomodulyatory v kompleksnoj terapii ORVI: vozmozhnosti primeneniya preparata Galavit. RMJ. 2013;(3):144. (In Russ).
15. Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Efficiency of Immunomodulatotors for Complex Therapy of Chronic Recurrent Cystitis in Women. Urologiia. 2019;(2):9-14
16. https://www.liguecancer.ch/fachpersonen/literatur/komplementaermedizin/publikationen/dokumentationen-fuer-fachpersonen/-dl-/fileadmin/downloads/sheets/galavit-cancer-immunotherapy.pdf
17. The National Toxicology Program. Luminol [521-31-3] Review of Toxicological Literature. https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/luminol_508.pdf
Review
For citations:
Tsvetov V.M., Kiselev Yu.Yu., Mirzaev K.B., Sychev D.A. Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):4-7. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-4-7
Views:
6420
Email this article 